home / stock / mrchf / mrchf news
Fujirebio Diagnostics, a subsidiary of H.U. Group ( OTC:MRCHF ) has initiated clinical testing , required for the submission of its new SARS-CoV-2 Antigen assay for FDA Emergency Use Authorization. More news on: H.U. Group Holdings, Inc., Healthcare stocks news, Read more ...
The FDA designates Miraca Holdings ( OTC:MRCHF ) subsidiary Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio (1-42/1-40) quantitative in vitro diagnostic test a Breakthrough Device as an aid in diagnosing Alzheimer's disease. More news on: Miraca Holdings, Inc., Healthcare stocks ...